Michael Hayden joins Med BioGene's board
This article was originally published in Clinica
Executive Summary
Canadian molecular diagnostics specialist Med BioGene has appointed Michael Hayden to its board of directors. Dr Hayden is a professor of medical genetics at the University of British Columbia, Vancouver, Canada, and director of a genetic research facility there, the Center for Molecular Medicine and Therapeutics. He has also served as the scientific director of the Canadian Genetic Diseases Network since it was founded in 1990, and is director and chief scientific officer of Xenon Pharmaceuticals, a privately-held biotech company. Vancouver-based Med BioGene's lead product is LungExpress Dx, a test to help improve staging for non-small cell lung cancer patients, identifying patients with a higher risk of mortality. The firm hopes to launch it in the US this year.